申请人:Sumitomo Pharmaceuticals Company, Limited
公开号:EP1514869A1
公开(公告)日:2005-03-16
The compound of the formula (I):
wherein W is a group of the following formula (VIII) binding to any possible position on the Q:
Q is, together with W, a group of the formula: -C(M=C(R3A)-N(R3)-, etc.;
R3A is H or optionally substituted lower alkyl; R4, R5, R6, and R7 are independently H or optionally substituted lower alkyl; R1 is optionally substituted lower alkyl, etc.; R2 is H, etc.; R3 is H, etc.; Ar is phenyl, etc., or a pharmaceutically acceptable salt thereof, where these compounds exhibiting β3-adrenoceptor-stimulating activity and being useful as a medicament for treatment of obesity, etc.
公式(I)的化合物:
其中W是以下公式(VIII)的基团,可以与Q的任何可能位置结合:
Q与W一起是以下公式的基团:-C(M=C(R3A)-N(R3)-等;
R3A是H或可选地取代的低级烷基;R4、R5、R6和R7独立的是H或可选地取代的低级烷基;R1是可选地取代的低级烷基等;R2是H等;R3是H等;Ar是苯基等,或其药物可接受的盐,其中这些化合物具有β3-肾上腺素受体刺激活性,并作为治疗肥胖等的药物有用。